This article is more than 5 years old. Information may no longer be current.

Pfizer announces VISION Function study of Macugen

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — A new trial will assess functional vision in patients taking pegaptanib for treatment for age-related macular degeneration, according to the drug’s marketers.

The trial of Macugen (pegaptanib, Pfizer/Eyetech), called the VISION Function study (VEGF Inhibition Study in Ocular Neovascularization Function) will be conducted in 18 countries and will include more than 300 patients with choroidal neovascularization secondary to AMD. The trial will assess near vision, reading speed, contrast sensitivity and distance visual acuity of patients with neovascular AMD, according to a press release from Pfizer.

“The design of this study will provide us with visual function and quality-of-life information for patients using Macugen,” said Ronald Buggage, MD, Pfizer’s global ophthalmology medical director, in the release. “We are also interested in assessing the value of Macugen in treating AMD patients at an earlier stage in the development of their disease.”

Macugen is currently approved to be administered in a 0.3 mg dose once every 6 weeks by intravitreal injection. It is co-promoted in the United States by Pfizer and Eyetech; outside the United States, Pfizer has exclusive marketing rights.